Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer

Cancer Research

Volumn 67, Issue 2, 2007, Pages 727-734

  Lorch, Jochen H ^a,c   Thomas, Tarita O ^b   Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ACTIN; ALPHA CATENIN; BETA CATENIN; BORTEZOMIB; DESMOGLEIN 2; DESMOPLAKIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; UVOMORULIN;

ARTICLE; CELL ADHESION; CELL DEATH; CELL INVASION; CELL LEVEL; CELL MIGRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUTH CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SQUAMOUS CELL CARCINOMA;

ADHERENS JUNCTIONS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; DESMOGLEIN 2; DESMOPLAKINS; DESMOSOMAL CADHERINS; DRUG SYNERGISM; FOCAL ADHESION KINASE 1; HUMANS; PYRAZINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TONGUE NEOPLASMS;

EID: 33846685893     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2162     Document Type: Article

References (46)

1. Depondt J, Shabana AH, Florescu-Zorila S, Gehanno P, Forest N. Down-regulation of desmosomal molecules in oral and pharyngeal squamous cell carcinomas as a marker for tumour growth and distant metastasis. Eur J Oral Sci 1999;107:183-93.
2. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998;153:333-9.
3. Nollet F, Berx G, van Roy F. The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun 1999;2:77-85.
4. Getsios S, Huen AC, Green KJ. Working out the strength and flexibility of desmosomes. Nat Rev Mol Cell Biol 2004;5:271-81.
5. Tsukamoto T, Nigam SK. Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome. J Biol Chem 1999;274:24579-84.
6. Akhtar N, Hotchin NA. RAC1 regulates adherens junctions through endocytosis of E-cadherin. Mol Biol Cell 2001;12:847-62.
7. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J Biol Chem 1997;272:24735-8.
8. Angers S, Thorpe CJ, Biechele TL, et al. The KLHL12-Cullin-3 ubiquitin ligase negatively regulates the Wnt-β-catenin pathway by targeting dishevelled for degradation. Nat Cell Biol 2006;8:348-57.
9. Lorch JH, Klessner J, Park JK, et al. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem 2004;279:37191-200.
10. Klessner JS, Stack MS, Green KJ. Epidermal growth factor receptor inhibition promotes desmosome adhesion by blocking MMP-dependent processing and internalization of desmoglein 2 in squamous cell carcinoma cells. J Invest Dermatol 2005;124:A153.
11. Brakebusch C, Fassler R. The integrin-actin connection, an eternal love affair. EMBO J 2003;22:2324-33.
12. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003;116:1409-16.
13. McLean GW, Carragher NO, Avizienyte E, et al. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005;5:505-15.
14. Watermann DO, Gabriel B, Jager M, et al. Specific induction of pp125 focal adhesion kinase in human breast cancer. Br J Cancer 2005;93:694-8.
15. Lark AL, Livasy CA, Calvo B, et al. Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res 2003;9:215-22.
16. Lark AL, Livasy CA, Dressier L, et al. High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol 2005;18:1289-94.
17. Livasy CA, Moore D, Cance WG, Lininger RA. Focal adhesion kinase Overexpression in endometrial neoplasia. Appl Immunohistochem Mol Morphol 2004;12:342-5.
18. Schlaepfer DD, Mitra SK, Ilic D. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 2004;1692:77-102.
19. Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004;14:92-101.
20. Agochiya M, Brunton VG, Owens DW, et al. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene 1999;18:5646-53.
21. Liu E, Cote JF, Vuori K. Negative regulation of FAK signaling by SOCS proteins. EMBO J 2003;22:5036-46.
22. Irby RB, Yeatman TJ. Increased Src activity disrupts cadherin/catenin- mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res 2002;62:2669-74.
23. Quadri SK, Bhattacharjee M, Parthasarathi K, Tanita T, Bhattacharya J. Endothelial barrier strengthening by activation of focal adhesion kinase. J Biol Chem 2003;278:13342-9.
24. Balzac F, Avolio M, Degani S, et al. E-cadherin endocytosis regulates the activity of Rap1:a traffic light GTPase at the crossroads between cadherin and integrin function. J Cell Sci 2005;118:4765-83.
25. Musto P, Falcone A, Sanpaolo G, et al. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leuk Res 2006;30:283-5.
26. Boccadoro M, Morgan G. Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005;5:18.
27. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695-704.
28. Kowalczyk AP, Bornslaeger EA, Borgwardt JE, et al. The amino-terminal domain of desmoplakin binds to plakoglobin and clusters desmosomal cadherin-plakoglobin complexes. J Cell Biol 1997;139:773-84.
29. Huen AC, Park JK, Godsel LM, et al. Intermediate filament-membrane attachments function synergistically with actin-dependent contacts to regulate intercellular adhesive strength. J Cell Biol 2002;159:1005-17.
30. Alwan HA, van Zoelen EJ, van Leeuwen JE. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem 2003;278:35781-90.
31. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1988;115:61-9.
32. Musto P, Falcone A, Sanpaolo G, et al. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leuk Res 2006;20:283-5.
33. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
34. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003;29 Suppl 1:3-9.
35. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
36. Fujita Y, Krause G, Scheffner M, et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002;4:222-31.
37. Eshkind L, Tian Q, Schmidt A, et al. Loss of desmoglein 2 suggests essential functions for early embryonic development and proliferation of embryonal stem cells. Eur J Cell Biol 2002;81:592-8.
38. Koeser J, Troyanovsky SM, Grund C, Franke WW. De novo formation of desmosomes in cultured cells upon transfection of genes encoding specific desmosomal components. Exp Cell Res 2003;285:114-30.
39. Biedermann K, Vogelsang H, Becker I, et al. Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J Pathol 2005;207:199-206.
40. Bryant DM, Stow JL. The ins and cuts of E-cadherin trafficking. Trends Cell Biol 2004;14:427-34.
41. Gallicano GI, Bauer C, Fuchs E. Rescuing desmoplakin function in extra-embryonic ectoderm reveals the importance of this protein in embryonic heart, neuro-epithelium, skin and vasculature. Development 2001;128:929-41.
42. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 2000;19:5606-13.
43. Owen JD, Ruest PJ, Fry DW, Hanks SK. Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol Cell Biol 1999;19:4806-18.
44. Aronsohn MS, Brown HM, Hauptman G, Kornberg LJ. Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx. Laryngoscope 2003;113:1944-8.
45. Moon HS, Park WI, Choi EA, Chung HW, Kim SC. The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas. Int J Gynecol Cancer 2003;13:640-6.
46. Avizienyte E, Wyke AW, Jones RJ, et al. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 2002;4:632-8.